PDF Email Page Print Friendly Page Contact
inbound investment/international: matters
Summary Professionals Matters News Events Publications
Ongoing
Private Equity Fund - Life Sciences
Representation of fundless sponsor in raising $100 million second strategic life sciences fund. The fund will invest in biotech, biologic and medical instruments industry segments worldwide, with investors primarily based in Asia.
Ongoing
Seegene - International Counsel
Designated outside counsel to Seegene, Inc., a Seoul-based molecular diagnostics company, in its international product distribution and technology licensing, M&A, corporate and capital markets matters. Seegene has developed innovative technologies for the detection of multiple pathogens (ACP (Annealing Control Primer)TM and DPO (Dual Specific Oligonucleotide)TM).
Ongoing
Non-U.S. Institutional Investors - Interest Acquisition
Representation of non-U.S. institutional investors in acquisitions of significant interests in U.S. based broker-dealers and investment managers.
Ongoing
Stelic Institute & Co. - International Counsel
Designated outside counsel to Stelic Institute & Co., a Tokyo-based bio-venture company specializing in regenerative medicine, in its international legal matters. Stelic is a fast-growing bio-ventures company with scientific research laboratories in the United States, Canada and Japan. Herrick advises Stelic on product and technology licensing matters, international licensing relationships, and on corporate structuring, equity issuance, capital markets, M&A and other matters.
2013
Multinational Insurance and Reinsurance Company - Capital Markets and Regulatory Advice
Ongoing capital markets and regulatory advice to the investment advisory unit of a multinational insurance and reinsurance company.
2007
French Pharma Company - U.S. Market Entry
Representation of a France-based pharmaceutical manufacturer in structuring its entry into the U.S. market, seeking to reduce or minimize exposure for a business whose principal products have higher-than-average exposure to products liability claims.